Nimodipine in Vestibular Schwanommas

Launched by MEDICAL UNIVERSITY OF VIENNA · Mar 13, 2021

Keywords

ClinConnect Summary

This clinical trial is studying the potential benefits of a medication called nimodipine during surgery for vestibular schwannomas, which are tumors that can affect hearing and facial movement. The trial aims to see if applying nimodipine directly to the nerves during surgery can help prevent problems like facial paralysis or hearing loss after the procedure. The study will involve 30 participants who are adults over 18 years old and have a specific size of vestibular schwannoma (between 10-25mm).

Participants in the trial will be randomly assigned to receive either nimodipine or a placebo (a harmless salt solution) during their surgery. Neither the patients nor the surgical team will know which treatment each participant receives. After the surgery, the effectiveness will be evaluated by checking how well the participants can hear and how well their facial nerve is functioning three months later. While there may be some mild side effects from nimodipine, the researchers believe that the benefits could outweigh these risks. If you're considering participating, it's important to discuss this with your healthcare provider to ensure you're a good fit for the study.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Age \> 18a
• • Vestibular schwannoma with maximum diameter of 10-25mm on MRI
• • Pre-operative audiogram
• • Informed consent
• Exclusion Criteria:
• • Contraindication for nimodipine application
• • Vestibularis schwannoma diameter \<10mm or \>25mm on MRI